Skip to main content

Advertisement

SpringerLink
Log in

Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

High-dose methotrexate (HD-MTX) therapy is widely used in patients with acute lymphoblastic leukemia (ALL) and lymphoma. However, some patients experience delayed MTX elimination, which requires treatment suspension or dose reduction to avoid organ damage. This single-center retrospective analysis reviewed the clinical data of 88 children with ALL or non-Hodgkin lymphoma who received a total of 269 courses of HD-MTX therapy between April 2008 and April 2019. HD-MTX was defined as MTX administration at 2.0, 3.0, or 5.0 g/m2 over a 24-h period, and delayed MTX elimination was defined as a serum MTX concentration ≥ 1.0 µmol/L at 48 h after the start of HD-MTX. Clinical factors were compared between courses with and without delayed MTX elimination. MTX elimination was delayed in 21 of the 269 courses (7.8%). Multivariate analysis showed that first HD-MTX course (OR 4.04), lower urine volume per BSA on the first day of HD-MTX administration (< 2,675 mL/m2, OR 5.10), higher total bilirubin (> 0.5 mg/dL, OR 5.11), lower eGFR (< 136 mL/min/1.73 m2, OR 3.90), higher dose of MTX(> 3.0 g/m2, OR 10.8), and lower urine volume per BSA on the next day of starting HD-MTX (< 2,107 mL/m2, OR 3.43) were independent risk factors for delayed MTX elimination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Petez C, Wang YM, Sutow WW, Herson J. Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials. 1978;1(2):107–11.

    Google Scholar 

  3. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

    Article  CAS  Google Scholar 

  4. Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, Fujita N, Akioka Y, Kaneko T, Honda M. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626–33.

    Article  CAS  PubMed  Google Scholar 

  5. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  6. Yanagimachi M, Goto H, Kaneko T, Naruto T, Sasaki K, Takeuchi M, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, Fujii H, Tanaka F, Goto S, Takahashi H, Mori M, Kai S, Yokota S. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013;98:702–7.

    Article  CAS  PubMed  Google Scholar 

  7. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67:44–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother. 1997;31:1261–2.

    Article  CAS  PubMed  Google Scholar 

  9. de Miguel D, García-Suárez J, Martín Y, Gil-Fernández JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with hematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant. 2008;23:3762–6.

    Article  PubMed  Google Scholar 

  10. Pauley JL, Panetta JC, Schmidt J, Kornegay N, Relling MV, Pui CH. Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol. 2004;54:146–52.

    Article  CAS  PubMed  Google Scholar 

  11. Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol. 2015;75:27–35.

    Article  CAS  PubMed  Google Scholar 

  12. Samantha R, Larry B, Nelly A, Debra A, Sean M, Dan D. Hypoalbminemia is sgnificantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95:2009–15.

    Article  Google Scholar 

  13. Hall JJ, Bolina M, Chatterley T, Jamali F. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors. Ann Pharmacother. 2017;51:163–78.

    Article  CAS  PubMed  Google Scholar 

  14. Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol. 1984;13:9–13.

    Article  CAS  PubMed  Google Scholar 

  15. Xu WQ, Zhang LY, Chen XY, Pan BH, Mao JQ, Song H, Li JY, Tang YM. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014;73:79–86.

    Article  CAS  PubMed  Google Scholar 

  16. Skärby T, Jönsson P, Hjorth L, Behrentz M, Björk O, Forestier E, Jarfelt M, Lönnerholm G, Höglund P. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003;51:311–20.

    Article  PubMed  Google Scholar 

  17. Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004;43:17–22.

    Article  PubMed  Google Scholar 

  18. Xu W, Tang Y, Song H, Shi S, Yang S. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688–93.

    Article  CAS  PubMed  Google Scholar 

  19. Laila H, Anders M, Lars M, Lars S, Kirsten S. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73:106–14.

    Article  Google Scholar 

  20. Sterba J, Dusek L, Demlova R, Valik D. Pretreatment plasma folate modulates the pharmacodynamics effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: ‘folate over rescue’ concept revisited. Clin Chem. 2006;52:692–700.

    Article  CAS  PubMed  Google Scholar 

  21. Valik D, Sterba J, Bajciova V, Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology. 2005;69:269–72.

    Article  CAS  PubMed  Google Scholar 

  22. Tsurusawa M, Gosho M, Mori T, Mitsui T, Sunami S, Kobayashi R, Fukano R, Tanaka F, Fujita N, Inada H, Koh K, Takimoto T, Saito A, Fujimoto J, Nakazawa A, Horibe K; lymphoma committee of the Japanese Pediatric Leukemia/lymphoma Study Group. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood non-Hodgkin lymphoma. Pediatr Blood Cancer. 2015; 62:279–284.

  23. Locasciulli A, Mura R, Fraschini D, Gornati G, Scovena E, Gervasoni A, Uderzo C, Masera G. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study. Haematologica. 1992;77(1):49–53.

    CAS  PubMed  Google Scholar 

  24. Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, Bocci G, Nardini D, Macchia P, Del Tacca M. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharmacol. 1996;37:409–14.

    Article  CAS  PubMed  Google Scholar 

  25. Toshiaki T, Atsushi Y, Kiyoshi I. Reference intervals of clinical tests in children determined by a latent reference value extraction method. J Jpn Pediatr Soc. 2008;112:1117–32.

    Google Scholar 

  26. Drost SA, Wentzell JR, Giguère P, McLurg DL, Sabloff M, Kanji S, Nguyen TT. Outcomes associated with reducing the urine alkalinization threshold in patients receiving high-dose methotrexate. Pharmacotherapy. 2017;37:684–91.

    Article  CAS  PubMed  Google Scholar 

  27. Ramsey LB, Panetta JC, Smith C, et al. Genomewide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121:898–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishi-ku, Sapporo, 003-0006, Japan

    Takaaki Nakano, Ryoji Kobayashi, Satoru Matsushima, Daiki Hori, Masato Yanagi, Daisuke Suzuki & Kunihiko Kobayashi

Authors
  1. Takaaki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryoji Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoru Matsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daiki Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masato Yanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daisuke Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kunihiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takaaki Nakano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakano, T., Kobayashi, R., Matsushima, S. et al. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int J Hematol 113, 744–750 (2021). https://doi.org/10.1007/s12185-020-03071-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-03071-w

Keywords

Search

Navigation